ArticleBiomicrofluidics2011
A microfluidic-based neurotoxin concentration gradient for the generation of an in vitro model of Parkinson's disease.
Article in Biomicrofluidics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 52 citations in OpenAlex.
- Microfluidic platform for understanding Parkinson's disease and α-synuclein conformation.Translational neurodegeneration · 2025Review
- Aging on Chip: Harnessing the Potential of Microfluidic Technologies in Aging and Rejuvenation Research.Advanced healthcare materials · 2025Review
- Regulation of BBB function and pathological evolution of PD by microenvironment "spatiotemporal gradient": unique advantages of microfluidic chips.Frontiers in aging neuroscience · 2025Review
- Neuropathogenesis-on-chips for neurodegenerative diseases.Nature communications · 2024Review
- Regulation of cell fate by cell imprinting approach in vitro.BioImpacts : BI · 2024Review
- Modeling Neurodegenerative Diseases UsingFrontiers in bioengineering and biotechnology · 2022Review
- The Synergy between Organ-on-a-Chip and Artificial Intelligence for the Study of NAFLD: From Basic Science to Clinical Research.Biomedicines · 2021Review
- Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson's Disease.Frontiers in pharmacology · 2021Review
- Human mini-brain models.Nature biomedical engineering · 2021Review
- Patient-Derived Induced Pluripotent Stem Cell-Based Models in Parkinson's Disease for Drug Identification.International journal of molecular sciences · 2020Review
- Recent advances in microfluidics for drug screening.Biomicrofluidics · 2019Review
- Multi-dimensional studies of synthetic genetic promoters enabled by microfluidic impact printing.Lab on a chip · 2017Article
- The Role of Microfluidics for Organ on Chip Simulations.Bioengineering (Basel, Switzerland) · 2017Review
- Screening applications in drug discovery based on microfluidic technology.Biomicrofluidics · 2016Review
- Microfluidic organs-on-chips.Nature biotechnology · 2014Article
- Using microfluidic chip to form brain-derived neurotrophic factor concentration gradient for studying neuron axon guidance.Biomicrofluidics · 2014Article
- Gradients of physical and biochemical cues on polyelectrolyte multilayer films generated via microfluidics.Lab on a chip · 2013Article
- Tunable, pulsatile chemical gradient generation via acoustically driven oscillating bubbles.Lab on a chip · 2013Article
- High-throughput study of alpha-synuclein expression in yeast using microfluidics for control of local cellular microenvironment.Biomicrofluidics · 2012Article
- From 3D cell culture to organs-on-chips.Trends in cell biology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we developed a miniaturized microfluidic-based high-throughput cell toxicity assay to create an in vitro model of Parkinson's disease (PD). In particular, we generated concentration gradients of 6-hydroxydopamine (6-OHDA) to trigger a process of neuronal apoptosis in pheochromocytoma PC12 neuronal cell line. PC12 cells were cultured in a microfluidic channel, and a concentration gradient of 6-OHDA was generated in the channel by using a back and forth movement of the fluid flow. Cellular apoptosis was then analyzed along the channel. The results indicate that at low concentrations of 6-OHDA along the gradient (i.e., approximately less than 260 μM), the neuronal death in the channel was mainly induced by apoptosis, while at higher concentrations, 6-OHDA induced neuronal death mainly through necrosis. Thus, this concentration appears to be useful for creating an in vitro model of PD by inducing the highest level of apoptosis in PC12 cells. As microfluidic systems are advantageous in a range of properties such as throughput and lower use of reagents, they may provide a useful approach for generating in vitro models of disease for drug discovery applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.